摘要:
Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.
摘要:
There is disclosed a process for the preparation of 5-substituted-1-azabicyclo[3.3.0]octanes of the Formula
wherein R¹ is a cyano radical or group of -CO₂R³, in which R³ is a lower alkyl group. The derivative is prepared by reacting 1,7-disubstituted-4-heptanone of the Formula
wherein X is a chlorine, bromine or iodine atom, or a group of -OSO₂R, in which R is a methyl, tolyl or tri-fuloromethyl radical, with a substituted acetic acid derivative of the Formula R¹CH₂CO₂Y wherein R¹ has the meaning as referred to; and Y is a hydrogen, sodium or potassium atom, or -NH₄, an alkali metal salt or ammonium salt of the derivative, in the presence of ammonia. Among the 5-substituted-1-azabicyclo[3.3.0]octanes, 5-cyanomethyl-1-azabicyclo[3.3.0]octane can be converted into 5-(2-aminoethyl)-1-azabicyclo[3.3.0]octane through a catalystic reduction which is carried out in atmospheric pressure, in alkali condition, and in the presence of Raney nickel.
摘要:
There is disclosed a process for the preparation of 5-substituted-1-azabicyclo[3.3.0]octanes of the Formula
wherein R¹ is a cyano radical or group of -CO₂R³, in which R³ is a lower alkyl group. The derivative is prepared by reacting 1,7-disubstituted-4-heptanone of the Formula
wherein X is a chlorine, bromine or iodine atom, or a group of -OSO₂R, in which R is a methyl, tolyl or tri-fuloromethyl radical, with a substituted acetic acid derivative of the Formula
R¹CH₂CO₂Y
wherein R¹ has the meaning as referred to; and Y is a hydrogen, sodium or potassium atom, or -NH₄, an alkali metal salt or ammonium salt of the derivative, in the presence of ammonia. Among the 5-substituted-1-azabicyclo[3.3.0]octanes, 5-cyanomethyl-1-azabicyclo[3.3.0]octane can be converted into 5-(2-aminoethyl)-1-azabicyclo[3.3.0]octane through a catalystic reduction which is carried out in atmospheric pressure, in alkali condition, and in the presence of Raney nickel.
摘要:
New intermediates, and processes therefor, provide an efficient method for deriving 4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indoles, which are themselves intermediates to useful CNS agents, from the Kornfeld-Woodward ketone and like compounds. Preferred embodiments provide means for the preparation of substantially pure enantiomers of the desired 4-amino-1,2,2a,3,4,5-hexahydrobenz[cd]indole.
摘要:
A compound of the formula: wherein R₁ and R₂ are independently selected from hydrogen, loweralkyl, cycloalkyl, loweralkenyl, adamantyl, aryl, substituted aryl, heterocyclic group, substituted alkyl, substituted amide, functionalized carbonyl, and nitrogen containing ring wherein R₁, R₂ and the adjacent nitrogen atom form a ring; R₁₁ is hydrogen, loweralkyl, or loweralkenyl; R₂₀ is hydrogen, loweralkyl, or loweralkenyl; B is -(CH₂) m -, substituted alkenylene, -QCH₂- wherein Q is O, S, NH or substituted amino, -CH₂Q- wherein Q is as defined or B is NH; Z is C=O, S(O)₂, or C=S; Ar is a heterocyclic group, aryl or substituted aryl; D is unsubstituted or substituted indol-3-yl, indolin-3-yl or oxindol-3-yl; and m is 0 to 4; or a pharmaceutically acceptable salt thereof.
摘要:
Provided are a compound used as a BCR-ABL inhibitor, namely a compound of formula (I), or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a pharmaceutical composition comprising the compound. Moreover, the present invention relates to a use of the compound in the preparation of a drug for treating BCR-ABL related diseases.